Is Benson Hill, Inc. overvalued or undervalued?

As of 15 November 2021, the valuation grade for Benson Hill, Inc. has moved from does not qualify to risky, indicating a significant shift in its assessment. The company appears to be overvalued, given its troubling financial ratios, including a P/E ratio of -0.0034, an EV to EBITDA of -0.13, and a ROE of -270.26%. These figures suggest that the company is struggling to generate profits and is facing substantial operational challenges.
In comparison to its peers, Benson Hill's valuation metrics stand out negatively. For instance, Longboard Pharmaceuticals, Inc. has a P/E ratio of -27.0419, while Absci Corp. shows a P/E of -3.2164, both indicating severe valuation concerns. Additionally, the company's recent performance has been dismal, with a year-to-date return of -96.25% compared to the S&P 500's modest gain of 2.44%. This stark contrast reinforces the notion that Benson Hill, Inc. is not only overvalued but also faces significant headwinds moving forward.